2025-12-17 - Analysis Report
Okay, here's a comprehensive analysis of TG Therapeutics Inc. (TGTX) based on the provided data, presented with simple numbers first, followed by analysis.

**1. Return Rate Comparison:**

*   **TGTX Cumulative Return:** 71.03%
*   **VOO (S&P 500) Cumulative Return:** 99.81%
*   **Divergence:** -32.4 (Relative Divergence: 16.9)
*   **Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

**Analysis:**

*   TGTX has underperformed the S&P 500 (VOO) over the analyzed period. The divergence of -32.4 indicates that the stock's cumulative return is significantly lower than the S&P 500's. The relative divergence of 16.9 suggests that the current divergence is near the lower end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta   | Cap(B) |
|------------|---------|--------|---------|--------|--------|
| 2015-2017  | -5.0%   | 73.5%  | -33.0%  | -0.0   | 1.3    |
| 2016-2018  | -12.0%  | 73.5%  | -27.0%  | -0.0   | 0.7    |
| 2017-2019  | 74.0%   | 74.1%  | 52.0%   | 0.0    | 1.8    |
| 2018-2020  | 316.0%  | 74.1%  | 293.0%  | 0.1    | 8.3    |
| 2019-2021  | 124.0%  | 74.1%  | 78.0%   | 0.3    | 3.0    |
| 2020-2022  | -71.0%  | 77.8%  | -71.0%  | -0.0   | 1.9    |
| 2021-2023  | -284.0% | 77.8%  | -285.0% | -1.1   | 2.7    |
| 2022-2024  | 56.0%   | 77.8%  | 36.0%   | -1.0   | 4.8    |
| 2023-2025  | 71.0%   | 80.7%  | 7.0%    | -0.1   | 4.9    |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  Highly volatile, with periods of significant growth (e.g., 2018-2020) and steep decline (e.g., 2021-2023).  This reflects the high-risk, high-reward nature of biotech companies.
*   **MDD (Maximum Drawdown):** Consistently high, indicating substantial potential for losses.
*   **Alpha:**  Indicates how the investment performs relative to its benchmark index.  Negative alpha means underperformance, while positive alpha indicates outperformance.  TGTX shows periods of both.
*   **Beta:** Measures volatility relative to the market. A beta close to 0 suggests the stock is not very correlated with the market.
*   **Cap(B):** Market capitalization in billions.

**2. Recent Stock Price Fluctuations:**

*   **Current Close:** 30.79
*   **Previous Close:** 31.41
*   **Change:** -1.97%
*   **5-day SMA:** 31.23
*   **20-day SMA:** 31.41
*   **60-day SMA:** 33.28

**Analysis:**

*   The stock is currently trading below its 5-day, 20-day, and 60-day moving averages, indicating a recent downward trend.  The negative change from the previous close further supports this. The closing price of 30.79 is below all moving averages which imply it is trending down.

**3. RSI, PPO, and Divergence Analysis:**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 36.76
*   **PPO:** 0.18
*   **Hybrid Signal:** Buy 100% of cash (32 shares - Very Safe - MRI:0.90). Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -1.6 (downward)
*   **Expected Return (%):** -136.5%

**Analysis:**

*   **MRI:** A medium investment recommendation suggests moderate risk.
*   **RSI:** An RSI of 36.76 indicates that the stock is nearing oversold conditions (typically below 30), potentially suggesting a possible rebound.
*   **PPO:**  A PPO of 0.18 suggests that the 20-day moving average is trading slightly below the 60-day moving average.
*   **Relative Divergence Change:** The negative change in relative divergence confirms a recent short-term decline relative to the comparison stock.
*   **Expected Return:** The very negative expected return suggests that, based on current analysis, the stock is not expected to perform well compared to the S&P 500 over the long term.

**4. Recent News & Significant Events:**

*   Headlines suggest a mixed outlook:
    *   Concerns raised about earnings ("The Earnings Caveat That Sent This Hot Biotech Diving").
    *   Analysis of strong financials despite recent weakness ("TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Has Shown Weakness Lately But Financials Look Strong").
    *   Competition progressing ("TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing (TGTX)").
    *   Potential for further stock decline ("TG Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go?").
    *   Recognition for growth ("Deloitte Fast 500 names TG Therapeutics (NASDAQ: TGTX) among North America’s fastest-growing firms").
    *   Institutional investment ("Marex Group plc Makes New $10.02 Million Investment in TG Therapeutics, Inc. $TGTX").

**Analysis:**

*   The news paints a complex picture.  While there's recognition of growth and some positive financial aspects, concerns about earnings, competition, and potential further stock decline are also present. Recent investment from Marex Group may indicate confidence in the company's future.

**4-2. Analyst Opinions:**

*   **Consensus:**  Neutral (information missing to give accurate rating but implied to be neutral as it is between 1 and 5)
*   **Target Price (avg/high/low):** 44.29 / 60.00 / 13.00

**Analysis:**

*   The average target price of $44.29 suggests potential upside from the current price of $30.79. However, the wide range between the high and low target prices reflects significant uncertainty among analysts.

**5. Recent Earnings Analysis:**

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-11-05 | 2.69 | 0.16 B$     |
| 2025-08-08 | 0.19 | 0.14 B$     |
| 2025-05-09 | 0.03 | 0.12 B$     |
| 2024-11-07 | 0.03 | 0.08 B$     |
| 2025-11-05 | 0.03 | 0.08 B$     |

**Analysis:**

*   The most recent EPS (2.69) is significantly higher than previous quarters, potentially driven by a one-time event. Revenues have generally been increasing, which is a positive sign.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-09-30 | $0.16B    | 82.63%        |
| 2025-06-30 | $0.14B    | 86.58%        |
| 2025-03-31 | $0.12B    | 87.14%        |
| 2024-12-31 | $0.11B    | 85.77%        |
| 2024-09-30 | $0.08B    | 88.86%        |

**Analysis:**

*   Revenue has been steadily increasing. Profit margins are very high, which is generally a positive indicator.

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-09-30 | $0.61B    | 64.37%  |
| 2025-06-30 | $0.28B    | 10.20%  |
| 2025-03-31 | $0.24B    | 2.13%   |
| 2024-12-31 | $0.22B    | 10.49%  |
| 2024-09-30 | $0.19B    | 2.02%   |

**Analysis:**

*   Equity has increased significantly in the most recent quarter. ROE (Return on Equity) is also very high in the most recent quarter, which is a strong indicator of profitability relative to shareholders' equity.

**7. Comprehensive Analysis:**

*   **Summary:** TGTX is a high-risk, high-reward biotech company. It has underperformed the S&P 500, exhibits high volatility, and shows a recent downward trend in its stock price.
*   **Positives:**  Recent earnings and revenue growth are encouraging, especially the significantly high EPS and ROE in the most recent quarter. High profit margins are also a positive sign. Recognition for growth and institutional investment suggest some confidence in the company.
*   **Negatives:**  High volatility, negative expected return, downward trend in stock price, and concerns raised in news articles indicate potential risks. Competition is also a factor to consider. The wide range in analyst target prices suggests considerable uncertainty.
*   **Overall:** Based on the data, TGTX appears to be a speculative investment. The company shows growth and profitability potential, but also carries significant risks. Investors should carefully consider their risk tolerance and conduct further due diligence before investing.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.